We serve Chemical Name:1-(3-acetyl-2-hydroxy-5-methylphenyl)ethanone CAS:55108-28-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-(3-acetyl-2-hydroxy-5-methylphenyl)ethanone
CAS.NO:55108-28-6
Synonyms:4-methyl-2,6-diacylphenol;4-methyl-2,6-diacetylphenol;2,6-diacetyl-p-cresol;1,3-diacetylcresol;1,3-diacetyl-2-hydroxy-5-methylbenzene;2,6-diacetyl-4-methylphenol;T0517-5137
Molecular Formula:C11H12O3
Molecular Weight:192.21100
HS Code:2914400090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:316.1ºC at 760 mmHg
Density:1.149g/cm3
Index of Refraction:1.546
PSA:54.37000
Exact Mass:192.07900
LogP:2.10580
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-methyl-2,6-diacylphenol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,T0517-5137 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,6-diacetyl-p-cresol Use and application,4-methyl-2,6-diacetylphenol technical grade,usp/ep/jp grade.
Related News: Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. 1-(3-acetyl-2-hydroxy-5-methylphenyl)ethanone manufacturer Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. 1-(3-acetyl-2-hydroxy-5-methylphenyl)ethanone supplier Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact. 1-(3-acetyl-2-hydroxy-5-methylphenyl)ethanone vendor Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. 1-(3-acetyl-2-hydroxy-5-methylphenyl)ethanone factory Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.